We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System
Read MoreHide Full Article
Key Takeaways
Hyperfine received FDA clearance for its next-generation Swoop Portable MR Imaging system.
HYPR's new Swoop system uses OptiVu AI to enhance image resolution, speed, and diagnostic utility.
Hyperfine aims to expand clinical use with a compact, mobile design suited for diverse care settings.
Hyperfine (HYPR - Free Report) recently announced FDA 510(k) clearance for its next-generation Swoop Portable MR Imaging system. The clearance covers an entirely new portable magnetic resonance imaging (MRI) scanner powered by Hyperfine’s proprietary OptiVu AI software, delivering the company’s highest level of image quality, functionality, and usability to date.
The FDA clearance strengthens Hyperfine’s commitment to revolutionizing bedside imaging by enabling rapid, low-field MRI capabilities without the logistical hurdles of traditional systems. With enhanced workflow, usability, and advanced AI-driven imaging, the next-gen Swoop system is positioned to bring greater clinical utility and operational efficiency to hospitals and care teams.
Likely Trend of HYPR Stock Following the News
Following the announcement, shares of the company moved 41% north and closed at $0.85 on Monday’s closing. Shares of the company have lost 3.4% in the year-to-date period compared with the industry’s 9.7% decline. The S&P 500 has gained 0.4% in the same time frame.
This FDA clearance positions Hyperfine for long-term growth by significantly enhancing the clinical appeal and marketability of its Swoop system, enabling broader adoption across hospitals, emergency departments, and global health systems. The improved image quality, AI-driven diagnostics, and ease of use make the system more competitive against conventional MRI, potentially accelerating sales, expanding reimbursement opportunities, and opening new revenue streams.
HYPR currently has a market capitalization of $46.89 billion. In the trailing four quarters, HYPR delivered an average earnings surprise of 3.1%.
Image Source: Zacks Investment Research
More on the Next-Generation Swoop System
The newly FDA-cleared next-generation Swoop Portable MR Imaging system represents a major technological advancement in bedside brain imaging. The system features a newly engineered hardware platform combined with the proprietary Optive AI software. This integration delivers the highest signal-to-noise ratio to date, resulting in exceptional image quality with improved resolution, uniformity, and faster acquisition times. These enhancements are designed to meet the growing demand for high-performance imaging solutions in varied healthcare environments where traditional MRI access is limited or delayed.
The upgraded Swoop system is tailored to be user- and patient-centric. It is optimized to scan a broad patient population, including pediatric, elderly, or anxious individuals, making it highly valuable in settings where patient compliance and comfort are crucial. Its compact, mobile design eliminates the need for patient transport, enabling clinicians to acquire brain scans directly at the point of care. This capability is particularly beneficial in emergency departments, ICUs, neurology offices, and even rural or under-resourced locations.
The system's development was shaped through collaboration with leading institutions such as Jefferson Abington, and is actively used in the Hyperfine-sponsored NEURO PMR study. Early results from these studies report highly positive feedback from clinicians and patients alike, with notable improvements in diagnostic efficiency and patient comfort.
Favorable Industry Prospects for HYPR
Per a report by Precedence Research, the global portable MRI market size accounted for $4.34 billion in 2025, and is expected to be worth around $7 billion by 2034, registering a CAGR of 5.44% between 2024 and 2034.
Given the market potential, HYPR is likely to witness a boost in its imaging business with the FDA-cleared Swoop system.
HYPR’s Zacks Rank & Key Picks
Currently, HYPR carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CVS Health has a long-term estimated growth rate of 11.4%. CVS’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 70.9%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hyperfine Stock Rises After FDA Clears Next-Gen Swoop MRI System
Key Takeaways
Hyperfine (HYPR - Free Report) recently announced FDA 510(k) clearance for its next-generation Swoop Portable MR Imaging system. The clearance covers an entirely new portable magnetic resonance imaging (MRI) scanner powered by Hyperfine’s proprietary OptiVu AI software, delivering the company’s highest level of image quality, functionality, and usability to date.
The FDA clearance strengthens Hyperfine’s commitment to revolutionizing bedside imaging by enabling rapid, low-field MRI capabilities without the logistical hurdles of traditional systems. With enhanced workflow, usability, and advanced AI-driven imaging, the next-gen Swoop system is positioned to bring greater clinical utility and operational efficiency to hospitals and care teams.
Likely Trend of HYPR Stock Following the News
Following the announcement, shares of the company moved 41% north and closed at $0.85 on Monday’s closing. Shares of the company have lost 3.4% in the year-to-date period compared with the industry’s 9.7% decline. The S&P 500 has gained 0.4% in the same time frame.
This FDA clearance positions Hyperfine for long-term growth by significantly enhancing the clinical appeal and marketability of its Swoop system, enabling broader adoption across hospitals, emergency departments, and global health systems. The improved image quality, AI-driven diagnostics, and ease of use make the system more competitive against conventional MRI, potentially accelerating sales, expanding reimbursement opportunities, and opening new revenue streams.
HYPR currently has a market capitalization of $46.89 billion. In the trailing four quarters, HYPR delivered an average earnings surprise of 3.1%.
Image Source: Zacks Investment Research
More on the Next-Generation Swoop System
The newly FDA-cleared next-generation Swoop Portable MR Imaging system represents a major technological advancement in bedside brain imaging. The system features a newly engineered hardware platform combined with the proprietary Optive AI software. This integration delivers the highest signal-to-noise ratio to date, resulting in exceptional image quality with improved resolution, uniformity, and faster acquisition times. These enhancements are designed to meet the growing demand for high-performance imaging solutions in varied healthcare environments where traditional MRI access is limited or delayed.
The upgraded Swoop system is tailored to be user- and patient-centric. It is optimized to scan a broad patient population, including pediatric, elderly, or anxious individuals, making it highly valuable in settings where patient compliance and comfort are crucial. Its compact, mobile design eliminates the need for patient transport, enabling clinicians to acquire brain scans directly at the point of care. This capability is particularly beneficial in emergency departments, ICUs, neurology offices, and even rural or under-resourced locations.
The system's development was shaped through collaboration with leading institutions such as Jefferson Abington, and is actively used in the Hyperfine-sponsored NEURO PMR study. Early results from these studies report highly positive feedback from clinicians and patients alike, with notable improvements in diagnostic efficiency and patient comfort.
Favorable Industry Prospects for HYPR
Per a report by Precedence Research, the global portable MRI market size accounted for $4.34 billion in 2025, and is expected to be worth around $7 billion by 2034, registering a CAGR of 5.44% between 2024 and 2034.
Given the market potential, HYPR is likely to witness a boost in its imaging business with the FDA-cleared Swoop system.
HYPR’s Zacks Rank & Key Picks
Currently, HYPR carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation (CVS - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and AngioDynamics (ANGO - Free Report) .
CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CVS Health has a long-term estimated growth rate of 11.4%. CVS’s earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%.
Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank #1.
Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%.
AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 70.9%.